Search Clinical Trials in the European Union

3-6 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
261-280 of 331 trials

Ataxia-Telangiectasia: N-Acetyl-L-Leucine Study

We are studying whether N-Acetyl-L-Leucine can improve symptoms and quality of life for people with Ataxia-Telangiectasia. The trial will also assess the safety of this treatment.

Ataxia Telangiectasia3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Dexamethasone for Severe Burns

We are studying whether early treatment with dexamethasone can help reduce serious complications and death in patients with severe burns. This trial will also look at its effects on infections and recovery times.

Severe Burns3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Idiopathic Hypersomnia: TAK-360 Study

We are testing a new medication, TAK-360, for people with idiopathic hypersomnia to see if it helps reduce excessive daytime sleepiness and improve overall condition. The study will also monitor the safety and tolerability of the treatment.

Idiopathic Hypersomnia3-6 monthsEfficacy phase (II)Investigational MedicinesPartially RemoteNeurology

Post-COVID-19 Syndrome: Vericiguat Study

We are investigating whether Vericiguat can improve physical function and reduce fatigue in individuals with post-COVID-19 syndrome compared to a placebo. This study aims to assess various aspects of health and safety related to the treatment.

Post-COVID-19 Syndrome3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteCardiologyInternal MedicinePulmonology

COVID-19: Ibuzatrelvir Study for High-Risk Patients

We are investigating whether ibuzatrelvir can help reduce symptoms and prevent severe illness in non-hospitalized adults and adolescents with COVID-19. This study compares the medication to a placebo to see how effective it is.

COVID-193-6 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal Medicine

Multiple Sclerosis Spasticity: BMS-986368 Study

We are evaluating a new oral medication for spasticity in people with multiple sclerosis. The study aims to see if it improves symptoms and overall function compared to a placebo.

Multiple SclerosisMultiple Sclerosis Spasticity3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteNeurologyRheumatology

Psilocybin for Depression in Cancer Patients

We are studying whether psilocybin can quickly improve depression in people with cancer compared to ketamine and midazolam. The trial will also look at its effects on quality of life and overall well-being.

Depression Related to Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPsychiatry

Solid Cancers: NI-1801 Antibody Study

We are testing a new antibody treatment for patients with solid cancers to see how well it works alone and with other therapies. This study aims to understand its safety and potential benefits.

Malignant Solid Tumor3-6 monthsSafety phase (I)Oncology

Kidney Health After Transplant: Dapagliflozin Study

We are studying how dapagliflozin affects kidney structure and inflammation in patients with impaired kidney function one year after transplantation. This research may help us understand better treatments for kidney transplant recipients.

Chronic Kidney Disease (CKD)3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyNephrology

Chronic Migraine: CGRP Monoclonal Antibody and Botox Combination Therapy

We are investigating whether a combination of CGRP monoclonal antibodies and Botox can reduce the number of migraine days for adults with chronic migraines. This study compares the effects of this dual therapy to a single treatment with CGRP monoclonal antibodies.

Chronic Migraine3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Premature Ejaculation: BP1.4979 Study

We are testing a new medication for adult men with primary premature ejaculation to see if it improves ejaculatory control and sexual satisfaction compared to a placebo.

Premature Ejaculation3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatryUrology

Ozone Therapy for Chemotherapy-Induced Pain Relief

We are studying whether adding ozone therapy helps cancer patients with painful neuropathy feel better and improve their quality of life. This trial will also look at the costs and safety of this treatment.

Chemotherapy-Induced Peripheral Neuropathy3-6 monthsEfficacy phase (II)Confirmation phase (III)Standard MedicinesNeurologyOncology

Prostate Cancer: Ebastine with Docetaxel or Cabazitaxel

We are studying a new treatment combining ebastine with either docetaxel or cabazitaxel for men with metastatic castration-resistant prostate cancer. The goal is to evaluate how this combination affects cancer markers and PSA levels.

Hormone-Refractory Prostate Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Cancer Anorexia: ART27.13 Cannabinoid Study

We are testing a new synthetic cannabinoid to see if it helps patients with cancer gain weight and improve appetite. The study also looks at the safety and quality of life for participants.

Cancer Anorexia3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Linaprazan Glurate: Interaction with Antibiotic

We are investigating how a new medication affects the way an approved antibiotic works in healthy individuals. This study may help us understand better drug interactions.

Helicobacter Pylori InfectionGastroesophageal Reflux Disease (GERD)3-6 monthsSafety phase (I)GastroenterologyInternal Medicine

Atorvastatin for Patients with Chronic Myeloproliferative Neoplasms

We are studying whether atorvastatin can improve health markers in patients with specific blood disorders. This trial looks at its effects alongside standard treatments to see how it may help manage symptoms and disease progression.

Blood Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyInternal Medicine

Multiple Sclerosis: CBD for Sleep Quality

We are investigating whether cannabidiol (CBD) can improve sleep quality in patients with multiple sclerosis. This study aims to help those struggling with sleep issues related to their condition.

Insomnia3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Cirrhosis: Carvedilol for Preventing Digestive Bleeding

We are studying whether Carvedilol can help prevent digestive bleeding in patients with cirrhosis. The trial measures its effects on liver pressure and overall tolerance over three months.

Cirrhotic Portal Hypertension3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Esophageal Cancer: Tislelizumab for Elderly Patients

We are studying Tislelizumab to see if it helps elderly patients with advanced esophageal cancer who cannot receive chemotherapy. The trial aims to assess survival rates and quality of life improvements.

Esophageal Squamous Cell Carcinoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

HER2-Positive Metastatic Breast Cancer: [177Lu]Lu-ABY-271 Treatment

We are studying a new treatment to see if it is safe and how it distributes in the body for patients with HER2-positive metastatic breast cancer. This trial will help us understand its effects on tumors and normal organs.

HER2-positive Metastatic Breast Cancer3-6 monthsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology